Eli Lilly sues four compounding pharmacies over copycat weight-loss drugs

Eli Lilly has filed four lawsuits accusing an Arizona weight-loss clinic and three online sellers of illegally selling products that contain a Lilly molecule still under investigation and not yet approved for use in any drug ^[1]. Lilly says the sales endanger consumers and amount to a "mockery of safety guidelines" ^[1].

The cases were reported by Law360 on October 9, 2026 ^[1]. One defendant is described as an Arizona weight-loss clinic, and the other three as online sellers ^[1]. The report does not name the clinic or the sellers, does not identify the courts where the four suits were filed, and does not give case numbers ^[1]. It also does not say how much money Lilly is seeking, whether the company is asking a court to shut the sales down, or whether any defendant has responded ^[1]. The dates the four suits were filed have not been reported ^[1].

The products at issue are described only as containing an investigational molecule that has not been approved for use in any drug ^[1]. The molecule is not named ^[1]. It therefore has not been reported whether the products are compounded versions of tirzepatide — the active ingredient in Mounjaro and Zepbound — compounded semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus, or something else ^[1]. Whether any of the defendants operates as a compounding pharmacy also has not been disclosed ^[1]. Law360's headline describes the cases as alleging illegal weight-loss drug sales, which indicates the products were marketed for weight loss ^[1].

Why it matters for patients

These suits target sellers rather than a drugmaker, so any direct effect would fall first on the clinic, the three online sellers and their customers ^[1]. If a court agrees the sales were illegal, the products described in the suits could stop being sold by those businesses ^[1]. Whether those customers would have another source for the same product has not been reported ^[1].

The cases also turn on a question a patient cannot answer from a label — whether a product is an FDA-approved medicine or a substance that has not been approved in any drug ^[1]. The reporting states that the molecule involved is not approved in any drug and does not say what testing or oversight, if any, applied to what the defendants sold ^[1]. The reporting also does not say whether any approved Lilly medicine is involved ^[1].

What happens next

No schedule has been reported for any of the four cases. Hearing dates, trial dates and court assignments have not been disclosed, and the report does not say whether Lilly plans to file more suits ^[1]. The molecule at the center of the cases has not been publicly identified in the reporting ^[1].